624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Outcomes Data

877 ASH denotes this abstract as clinically relevant

Anna Santarsieri, Katherine Sturgess, Pauline Brice, et al.

Even if, according to the authors, this is a retrospective study, replacing procarbazine with dacarbazine probably does not limit the efficacy of eBPP and could have some toxicity benefits. Despite the clear preference to offer this regimen in advanced high-risk stages: With a median follow-up time of almost 2 years with eBPDac, the study authors observed a similar PFS and OS compared to HD18. However, survival prognoses are better compared to 18-59 year old RAHL patients, suggesting that eBPDac is a highly effective therapy for the treatment of Hodgkin lymphoma.


878 ASH denotes this abstract as clinically relevant

Sanjal H Desai, Michael A Spinner, Kevin A. David, et al.

Compared to conventional chemotherapy (CT), BV/Nivo achieves a higher CR rate and better PFS after ASCT. This combination can lead to durable remissions in patients with CR prior to ASCT. Although BBV had a higher response rate, survival after ASCT was similar to that of conventional CT. BV demonstrated lower response rates compared to CT. According to the authors, novel salvage therapies such as BV/Nivo and BBV may be preferable to conventional CT for R/R-cHL.


879 ASH denotes this abstract as clinically relevant

Julia Driessen, Fer de Wit, Alex F. Herrera, et al.

BV plus salvage chemotherapy followed by ASCT appears to increase PFS in relapsed cHL patients. However, this is not the case in primary refractory patients. It is reasonable to assume that other treatment modalities such as checkpoint inhibitors (CPI) should be considered in chemotherapy-resistant patients.
The authors suggest that the increase in OS after BV could be due to advances in treatment over time, since at the time of the studies in the chemo cohort, no novel therapies were available for patients who have failed ASCT.
The strong prognostic value of pre-ASCT-CMR for PFS is confirmed in this study. Prognostic factors for PFS and for achieving pre-ASCT-CMR are B symptoms, stage, and primary refractory disease.



Salim Kanoun, Alina Berriolo-Riedinger, Anne Ségolène Cottereau, et al.

At the start of the study, tumor burden (TMTV) and dissemination (SDmax) were assessed using the 18FDG-PET. These parameters enable the outcome of patients with advanced HL to be predicted. This is independent of an early response to treatment. In doing so, this parameters overcome the prognostic value of IPS and could be included in new prognostic scores. This would allow personalized therapy for advanced Hodgkin lymphoma.



Andrea C. Lo, Amy Liu, PhD, Qi Liu, M.Sc, et al.

Go to abstract to see the results.



Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, et al.

Go to abstract to see the results.